Evidence map›Paper›PMID 28118838›Full record

ArticleBMC health services research2017

The cost-effectiveness of changes to the care pathway used to identify depression and provide treatment amongst people with diabetes in England: a model-based economic evaluation.

Ben Kearns, R Rafia, J Leaviss, L Preston, J E Brazier, S Palmer, R Ara

Open access · goldAbstract read
In one paragraph

Article in BMC health services research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
14.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Comorbid depression in medical diseases.Nature reviews. Disease primers · 2020
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ben KearnsSchool of Health and Related Research, University of Sheffield, Sheffield, UK, S1 4DA. b.kearns@sheffield.ac.uk.ORCID 0000-0001-7730-668X
R RafiaSchool of Health and Related Research, University of Sheffield, Sheffield, UK, S1 4DA.
J LeavissSchool of Health and Related Research, University of Sheffield, Sheffield, UK, S1 4DA.
L PrestonSchool of Health and Related Research, University of Sheffield, Sheffield, UK, S1 4DA.
J E BrazierSchool of Health and Related Research, University of Sheffield, Sheffield, UK, S1 4DA.
S PalmerCentre for Health Economics, University of York, Heslington, York, UK, YO10 5DD.
R AraSchool of Health and Related Research, University of Sheffield, Sheffield, UK, S1 4DA.
University of Sheffield · GBUniversity of York · GB

Funding

Department of Health [UK]
6 · The paper itself

Abstract

backgroundDiabetes is associated with premature death and a number of serious complications. The presence of comorbid depression makes these outcomes more likely and results in increased healthcare costs. The aim of this work was to assess the health economic outcomes associated with having both diabetes and depression, and assess the cost-effectiveness of potential policy changes to improve the care pathway: improved opportunistic screening for depression, collaborative care for depression treatment, and the combination of both.

methodsA mathematical model of the care pathways experienced by people diagnosed with type-2 diabetes in England was developed. Both an NHS perspective and wider social benefits were considered. Evidence was taken from the published literature, identified via scoping and targeted searches.

resultsCompared with current practice, all three policies reduced both the time spent with depression and the number of diabetes-related complications experienced. The policies were associated with an improvement in quality of life, but with an increase in health care costs. In an incremental analysis, collaborative care dominated improved opportunistic screening. The incremental cost-effectiveness ratio (ICER) for collaborative care compared with current practice was £10,798 per QALY. Compared to collaborative care, the combined policy had an ICER of £68,017 per QALY.

conclusionsPolicies targeted at identifying and treating depression early in patients with diabetes may lead to reductions in diabetes related complications and depression, which in turn increase life expectancy and improve health-related quality of life. Implementing collaborative care was cost-effective based on current national guidance in England.

Indexed as

Mass ScreeningComorbidityCost-Benefit AnalysisDepressionDiabetes Mellitus, Type 2EnglandHealth Care CostsHumansModels, EconomicPolicy MakingQuality ImprovementQuality of LifeCollaborative careDepressionDiabetes mellitusHealth economicsMass screening

Identifiers

PMID28118838
PMCPMC5259945
OpenAlexW2581059377

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.